001     162760
005     20240320115514.0
024 7 _ |a 10.1111/ene.15089
|2 doi
024 7 _ |a pmid:34472165
|2 pmid
024 7 _ |a 1351-5101
|2 ISSN
024 7 _ |a 1468-1331
|2 ISSN
024 7 _ |a 1471-0552
|2 ISSN
024 7 _ |a altmetric:112843889
|2 altmetric
037 _ _ |a DZNE-2021-01416
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Vöglein, Jonathan
|0 P:(DE-2719)2811820
|b 0
|e First author
245 _ _ |a Seizure prevalence in neurodegenerative diseases-a study of autopsy proven cases.
260 _ _ |a Oxford
|c 2022
|b Blackwell Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655207986_925
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 1468-1331 not unique: **2 hits**. (CC BY-NC)
520 _ _ |a Knowledge about the seizure prevalence in the whole symptomatic course, from disease onset to death, in neurodegenerative diseases (ND) is lacking. Therefore, the aim was to investigate seizure prevalence and associated clinical implications in neuropathologically diagnosed ND.Clinical records of cases from the Neurobiobank Munich, Germany, were analyzed. Neuropathological diagnoses of the assessed cases included Alzheimer disease (AD), corticobasal degeneration (CBD), frontotemporal lobar degeneration (FTLD), Lewy body disease (LBD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Seizure prevalence during the whole symptomatic disease phase was assessed and compared amongst ND. Associations between first clinical symptom and seizure prevalence and between seizures and disease duration were examined.In all, 454 patients with neuropathologically diagnosed ND and with available and meaningful clinical records were investigated (AD, n = 144; LBD, n = 103; PSP, n = 93; FTLD, n = 53; MSA, n = 36; CBD, n = 25). Seizure prevalence was 31.3% for AD, 20.0% for CBD, 12.6% for LBD, 11.3% for FTLD, 8.3% for MSA and 7.5% for PSP. Seizure prevalence was significantly higher in AD compared to FTLD (p = 0.005), LBD (p = 0.001), MSA (p = 0.005) and PSP (p < 0.001). No other significant differences regarding seizure prevalence were found between the studied ND. Cognitive first symptoms in ND were associated with an increased seizure prevalence (21.1% vs. 11.0% in patients without cognitive first symptoms) and motor first symptoms with a decreased seizure prevalence (10.3% vs. 20.5% in patients without motor first symptoms). Seizures were associated with a longer disease duration in MSA (12.3 vs. 7.0 years in patients without seizures; p = 0.017).Seizures are a clinically relevant comorbidity in ND, particularly in AD. Knowledge of the first clinical symptom in ND may allow for estimation of seizure risk.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
542 _ _ |i 2021-09-17
|2 Crossref
|u http://creativecommons.org/licenses/by-nc/4.0/
542 _ _ |i 2021-09-17
|2 Crossref
|u http://doi.wiley.com/10.1002/tdm_license_1.1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer disease
|2 Other
650 _ 7 |a epilepsy
|2 Other
650 _ 7 |a neurodegenerative diseases
|2 Other
650 _ 7 |a seizure prevalence
|2 Other
650 _ 7 |a seizures
|2 Other
650 _ 2 |a Autopsy
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Multiple System Atrophy: epidemiology
|2 MeSH
650 _ 2 |a Multiple System Atrophy: pathology
|2 MeSH
650 _ 2 |a Prevalence
|2 MeSH
650 _ 2 |a Seizures: epidemiology
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnosis
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: epidemiology
|2 MeSH
700 1 _ |a Kostova, Irena
|b 1
700 1 _ |a Arzberger, Thomas
|0 P:(DE-2719)2811333
|b 2
700 1 _ |a Noachtar, Soheyl
|b 3
700 1 _ |a Dieterich, Marianne
|0 P:(DE-2719)2811918
|b 4
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 5
700 1 _ |a Schmitz, Peer
|b 6
700 1 _ |a Ruf, Viktoria
|b 7
700 1 _ |a Windl, Otto
|0 P:(DE-2719)2812263
|b 8
700 1 _ |a Roeber, Sigrun
|b 9
700 1 _ |a Simons, Mikael
|0 P:(DE-2719)2811642
|b 10
700 1 _ |a Höglinger, Günter
|0 P:(DE-2719)2811373
|b 11
700 1 _ |a Danek, Adrian
|0 P:(DE-2719)2810712
|b 12
700 1 _ |a Giese, Armin
|0 P:(DE-2719)9000906
|b 13
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 14
|e Last author
773 1 8 |a 10.1111/ene.15089
|b Wiley
|d 2021-09-17
|n 1
|p 12-18
|3 journal-article
|2 Crossref
|t European Journal of Neurology
|v 29
|y 2021
|x 1351-5101
773 _ _ |a 10.1111/ene.15089
|g p. ene.15089
|0 PERI:(DE-600)2020241-6
|n 1
|p 12-18
|t European journal of neurology
|v 29
|y 2021
|x 1351-5101
856 4 _ |u https://onlinelibrary.wiley.com/doi/10.1111/ene.15089
856 4 _ |u https://pub.dzne.de/record/162760/files/DZNE-2021-01416.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/162760/files/DZNE-2021-01416.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:162760
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2811820
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811333
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2811918
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2810441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2812263
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2811642
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810712
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 13
|6 P:(DE-2719)9000906
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2811659
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NEUROL : 2021
|d 2022-11-11
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-11
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NEUROL : 2021
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-11
920 1 _ |0 I:(DE-2719)1111016
|k Clinical Dementia Research München
|l Clinical Dementia Research München
|x 0
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger 1
|l Translational Neurodegeneration
|x 1
920 1 _ |0 I:(DE-2719)1140013
|k Neuropathology / Brainbank
|l Neuropathology / Brainbank
|x 2
920 1 _ |0 I:(DE-2719)1111015
|k AG Höglinger 2
|l Coordinator of Clinical Parkinson Research
|x 3
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 4
920 1 _ |0 I:(DE-2719)1210003
|k AG Neumann
|l Molecular Neuropathology of Neurodegenerative Diseases
|x 5
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 6
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1140013
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1110001
980 _ _ |a I:(DE-2719)1210003
980 _ _ |a I:(DE-2719)1110008
980 1 _ |a FullTexts
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1528-1157.1992.tb06222.x
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.3233/JAD-170392
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e31828726f5
|2 Crossref
999 C 5 |1 Galvin E
|y 2019
|2 Crossref
|o Galvin E 2019
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.25945
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.3109/09540261.2013.776523
|2 Crossref
999 C 5 |1 Togasaki DM
|y 2000
|2 Crossref
|o Togasaki DM 2000
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.49.5.1284
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0000000000002638
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.20149
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0140-6736(99)04137-9
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0140-6736(00)82050-4
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1111/ene.14800
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00401-008-0460-5
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1038/nrn2535
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00401-011-0910-3
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0000000000004058
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.jalz.2011.10.007
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1002/mds.26987
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.44.11.2015
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/01.wnl.0000324625.00404.15
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S1474-4422(09)70238-8
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00401-007-0237-2
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e31827f0fd1
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1212/WNL.0b013e318204a36a
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.3233/JAD-170031
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1177/089198879400700407
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1080/13554790902971158
|2 Crossref
999 C 5 |1 Larner A
|y 2010
|2 Crossref
|o Larner A 2010
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.yebeh.2020.107311
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1002/ana.25157
|2 Crossref
999 C 5 |1 Beagle A
|y 2015
|2 Crossref
|o Beagle A 2015
999 C 5 |9 -- missing cx lookup --
|a 10.1001/archneur.1964.00460160003001
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/S0140-6736(18)32596-0
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00415-020-09937-7
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1002/gps.930081106
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1159/000117218
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1007/s00415-020-09937-7
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1111/epi.12550
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1111/j.1528-1167.2008.01945.x
|2 Crossref
999 C 5 |9 -- missing cx lookup --
|a 10.1016/j.yebeh.2010.07.016
|2 Crossref
999 C 5 |1 Wilden JA
|y 2012
|2 Crossref
|o Wilden JA 2012


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21